AnaptysBio Inc (NASDAQ:ANAB) has been given an average recommendation of “Buy” by the thirteen ratings firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and eight have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $112.00.

A number of equities analysts have weighed in on ANAB shares. Zacks Investment Research raised shares of DLH from a “sell” rating to a “hold” rating in a research note on Tuesday. Stifel Nicolaus downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating and reduced their price target for the company from $124.00 to $74.00 in a research report on Friday, June 21st. Credit Suisse Group reduced their price target on shares of from GBX 145 ($1.89) to GBX 105 ($1.37) and set a “neutral” rating for the company in a research report on Friday, June 21st. SunTrust Banks reissued a “buy” rating and set a $35.00 price target on shares of Whiting Petroleum in a research report on Monday, June 24th. Finally, Cantor Fitzgerald raised their price target on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, April 2nd.

Shares of NASDAQ ANAB traded up $0.43 on Friday, reaching $54.54. 164,616 shares of the company’s stock traded hands, compared to its average volume of 272,696. AnaptysBio has a 12 month low of $52.71 and a 12 month high of $110.00. The company has a 50 day moving average of $65.49. The stock has a market cap of $1.49 billion, a P/E ratio of -21.82 and a beta of 1.38.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.83) by $0.01. On average, analysts predict that AnaptysBio will post -3.76 earnings per share for the current year.

In related news, CEO Hamza Suria sold 22,428 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $73.76, for a total value of $1,654,289.28. Following the sale, the chief executive officer now owns 31,524 shares in the company, valued at $2,325,210.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Marco Londei sold 10,060 shares of the firm’s stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $73.06, for a total transaction of $734,983.60. Following the completion of the sale, the insider now owns 32,437 shares in the company, valued at approximately $2,369,847.22. The disclosure for this sale can be found here. 14.00% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Diag Capital Management LP purchased a new stake in AnaptysBio in the fourth quarter worth approximately $95,000. Amundi Pioneer Asset Management Inc. purchased a new stake in AnaptysBio in the first quarter worth approximately $110,000. SG Americas Securities LLC purchased a new position in shares of AnaptysBio during the 4th quarter worth $126,000. Bank of America Corp DE boosted its stake in shares of AnaptysBio by 141.2% during the 4th quarter. Bank of America Corp DE now owns 4,397 shares of the biotechnology company’s stock worth $281,000 after acquiring an additional 15,067 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in shares of AnaptysBio during the 1st quarter worth $290,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

Featured Story: How is the Producer Price Index calculated?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.